Ron Lanton, partner, Lanton Law, warns that ongoing lawsuits targeting vaccine policy could create ripple effects across FDA ...

The MFN executive order introduces uncertainty in pharma pricing strategies, necessitating careful risk assessment and ...

EMD Serono recently named Miguel Fernandez Alcalde as its new president. The new executive spoke with Pharmaceutical ...

The disease doesn’t have any FDA approved treatments, leaving families desperate for FDA to approve the treatment.

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing ...

Monument Therapeutics partners with FNIH to advance MT1988, a promising treatment for cognitive impairment in schizophrenia, ...

The global biotherapeutics company announced that it will seek to streamline operations as part of a broader transformation ...

The AAP diverges from CDC guidelines, advocating for Covid-19 vaccines in young children, igniting debate over vaccine policy ...

Why pharma and all stakeholders in the healthcare ecosystem should undertake a fundamental shift in how evidence to support ...

A look back and ahead at the growing trend—sparked recently by the GLP-1 trail—and new ways to harness this Rx access channel ...

Rob Abbott, CEO, ISPOR, highlights how AI is streamlining research and improving patient care while stressing the importance of human oversight.

Recent advancements in COPD treatments are providing patients with potential new first-line treatments. Pharmaceutical ...